Dokumeds

Dokumeds is a Latvia-based contract research organization (CRO) focused on the planning, execution, and support of clinical development programs. Established in 1995 and headquartered in Riga, the company developed from a European clinical-trial services provider into an international organization with operational capabilities in more than 30 countries across Europe, Africa, and other regions. Its work has primarily covered Phase I through Phase IV clinical trials for pharmaceutical, biotechnology, and medical-device companies. The company’s service model is intended to cover much of the clinical-development lifecycle rather than only one trial function. Its capabilities include feasibility assessment, study start-up, regulatory consulting and submissions, contract and payment administration, investigational-product and supply logistics, clinical training, medical monitoring, medical review, medical writing, pharmacovigilance, enrollment liaison, staff outsourcing, and site auditing. These services can be delivered as part of a full-service development program or through functional service arrangements in which a sponsor contracts Dokumeds for selected activities. Dokumeds expanded its geographic and operational reach over more than two decades. The organization has maintained offices or operational presence in countries including Latvia, Lithuania, Estonia, Poland, Ukraine, Russia, Bulgaria, Germany, Romania, and South Africa. This regional footprint positioned it to support multicountry studies, particularly where sponsors require local regulatory knowledge, clinical-site relationships, patient-enrollment support, and coordination across several national systems. The company’s positioning is that of a specialist international CRO combining broad clinical-development coverage with experience in European and neighboring markets. Its clients are sponsors developing medicines, biological products, and medical devices, although the available reference material does not identify specific customers, therapeutic-area specializations, trial results, or commercial performance figures. Dokumeds was acquired by Rho in 2021, linking the organization to a larger clinical-research and development-services group. The acquisition is the most clearly documented recent corporate milestone in the available material; details about post-acquisition branding, management, and operating structure are not specified.

Dokumeds was established in 1995 in Latvia as a provider of clinical research services. Over time, it developed capabilities across the clinical-trial lifecycle, supporting sponsors from early feasibility and study preparation through trial conduct, safety oversight, documentation, and close-out activities. Its principal client sectors have been pharmaceutical, biotechnology, and medical-device companies. The organization’s development was marked by gradual expansion in both geography and service scope. Rather than limiting its activities to a single national market, Dokumeds built an operating network spanning Central and Eastern Europe and later extending into other regions. The documented office network included Latvia, Lithuania, Estonia, Poland, Ukraine, Russia, Bulgaria, Germany, Romania, and South Africa. This footprint supported multicountry research programs and gave the company access to local regulatory, clinical-site, and patient-enrollment capabilities. Dokumeds’ service portfolio came to include feasibility work, study start-up, regulatory consulting and submissions, contract and payment management, investigational-product and supply logistics, training, medical monitoring, medical review, medical writing, pharmacovigilance, enrollment liaison, staff outsourcing, and site audits. In addition to offering comprehensive Phase I–IV clinical-development programs, the company provided individual functional services that sponsors could integrate with their own internal teams or other external suppliers. The company described its expansion as occurring over more than 25 years of operations, with geographic and operational growth accompanied by increases in staff and an improvement in employee-retention conditions. The available reference material characterizes Dokumeds as an international CRO with capabilities in more than 30 countries across Europe, Africa, and other markets. It does not provide detailed information about revenue, trial counts, therapeutic-area concentration, customers, or individual clinical outcomes. In 2021, Dokumeds was acquired by Rho. This transaction represents the clearest documented change in the company’s ownership history and placed Dokumeds within a larger clinical research and development-services platform. The available sources do not establish whether the Dokumeds name was fully retained, changed, or integrated into another Rho operating brand, nor do they identify the executives responsible for the company before or after the acquisition.

1. 2021Acquisition by Rho

   Rho acquires Dokumeds, bringing the CRO into the Rho clinical-development services group.

   Source
2. 1995Dokumeds is established

   Dokumeds begins operations in Latvia as a clinical research organization serving clinical-development programs.

   Source

An international clinical research organization providing full-service and functional support for pharmaceutical, biotechnology, and medical-device clinical development, with a strong European and transregional operating footprint.

• Full-service clinical development programsClinical research services

  Dokumeds provides coordinated support for Phase I through Phase IV clinical development. The service model can include trial planning, feasibility, study start-up, regulatory work, operational execution, medical oversight, safety activities, documentation, and site management. It is designed for pharmaceutical, biotechnology, and medical-device sponsors seeking an external organization to manage multiple components of a development program.

• Functional service provisionClinical outsourcing

  The company also supplies individual clinical-development functions rather than requiring sponsors to outsource an entire program. Referenced functions include feasibility, study start-up, regulatory submissions, contract and payment management, investigational-product and supply logistics, training, medical monitoring, medical review, medical writing, pharmacovigilance, enrollment liaison, staff outsourcing, and site audits.

• Regulatory and study start-up servicesRegulatory and operational support

  Dokumeds supports the preparatory stages of clinical trials through feasibility analysis, site and country assessment, study start-up coordination, and regulatory consultancy and submissions. These services are intended to help sponsors assess operational viability and move studies toward activation across multiple national markets.

• Medical and safety servicesMedical oversight and pharmacovigilance

  Medical monitoring, medical review, medical writing, and pharmacovigilance form part of Dokumeds’ clinical and safety-support offering. These functions contribute to ongoing medical oversight, clinical documentation, safety assessment, and the handling of information generated during development programs.

• 2021Joining the Rho groupM&A

  After more than two decades of expansion as an independent European CRO, Dokumeds was acquired by Rho.

  What changed. Rho acquired Dokumeds and incorporated the company into its broader clinical-development services platform.

  Aftermath. The acquisition changed Dokumeds’ ownership. The available source does not provide transaction value, integration details, or subsequent management changes.

  Source

• 2021Rho acquires Dokumeds

  Dokumeds was acquired by Rho, connecting the Latvia-based clinical research organization with the broader Rho clinical-development services group.

  M&A
  Source

1. Dokumeds
2. Dokumeds official website